V C Jordan Selected Research

Raloxifene Hydrochloride (Evista)

1/2007	Beyond raloxifene for the prevention of osteoporosis and breast cancer.
12/2003	Changing role of the oestrogen receptor in the life and death of breast cancer cells.
6/2002	Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
12/2001	The past, present, and future of selective estrogen receptor modulation.
12/2001	Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
10/2001	Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
10/2001	Raloxifene for the treatment and prevention of breast cancer?
6/2001	Tamoxifen to raloxifene and beyond.
1/2001	Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
11/2000	Progress in the prevention of breast cancer: concept to reality.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

V C Jordan Research Topics

Disease

42	Breast Neoplasms (Breast Cancer) 10/2016 - 01/2000
17	Neoplasms (Cancer) 03/2014 - 05/2000
11	Osteoporosis 01/2007 - 01/2000
7	Endometrial Neoplasms (Endometrial Cancer) 06/2002 - 01/2000
6	Coronary Disease (Coronary Heart Disease) 12/2001 - 11/2000
1	Ductal Carcinoma 01/2001
1	Postmenopausal Osteoporosis 01/2001
1	Male Breast Neoplasms (Male Breast Cancer) 01/2001
1	Hypertriglyceridemia 09/2000
1	Weight Loss (Weight Reduction) 07/2000
1	Body Weight (Weight, Body) 07/2000
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2000
1	Bone Fractures (Bone Fracture) 01/2000
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2000

Drug/Important Bio-Agent (IBA)

29	Tamoxifen FDA LinkGeneric 02/2014 - 01/2000
14	Raloxifene Hydrochloride (Evista)FDA Link 01/2007 - 01/2000
14	Selective Estrogen Receptor Modulators (SERM)IBA 01/2007 - 01/2000
12	Estrogens (Estrogen)FDA Link 02/2005 - 01/2000
11	Estrogen ReceptorsIBA 02/2014 - 01/2000
10	Hormones (Hormone)IBA 10/2016 - 01/2000
9	Estradiol (Delestrogen)FDA LinkGeneric 09/2014 - 01/2000
8	Estrogen Receptor Modulators (Antiestrogen)IBA 06/2002 - 05/2000
5	Pharmaceutical PreparationsIBA 03/2014 - 05/2000
4	Complementary DNA (cDNA)IBA 10/2016 - 09/2000
4	Estrogen Receptor alphaIBA 08/2002 - 05/2001
3	Protein Kinase C-alphaIBA 10/2016 - 09/2000
3	afimoxifene (hydroxytamoxifen)IBA 09/2014 - 05/2001
3	DNA (Deoxyribonucleic Acid)IBA 09/2014 - 05/2013
3	Fulvestrant (Faslodex)FDA Link 10/2001 - 01/2000
2	Paclitaxel (Taxol)FDA LinkGeneric 10/2016 - 03/2014
2	triphenylethyleneIBA 09/2014 - 12/2000
2	Aromatase InhibitorsIBA 02/2005 - 05/2000
2	Aromatase (CYP19)IBA 02/2005 - 01/2001
2	CholesterolIBA 12/2001 - 01/2000
2	LY 353381 (LY353381)IBA 12/2001 - 08/2001
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 10/2001 - 06/2001
2	Capsules (Microcapsules)IBA 08/2001 - 11/2000
2	Transforming Growth Factor alpha (TGF-alpha)IBA 07/2001 - 05/2001
2	IsoenzymesIBA 06/2001 - 09/2000
2	Triglycerides (Triacylglycerol)IBA 09/2000 - 01/2000
1	Biological ProductsIBA 09/2014
1	Taxoids (Taxanes)IBA 03/2014
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 02/2014
1	Cytostatic AgentsIBA 07/2013
1	Small Interfering RNA (siRNA)IBA 07/2013
1	Estrogen Receptor betaIBA 07/2013
1	LigandsIBA 05/2013
1	bisphenol AIBA 05/2013
1	SteroidsIBA 03/2004
1	SolutionsIBA 07/2003
1	Messenger RNA (mRNA)IBA 06/2002
1	Protein Kinases (Protein Kinase)IBA 10/2001
1	baysilon (polydimethylsiloxane)IBA 08/2001
1	LY 117018IBA 08/2001
1	benzothiopheneIBA 08/2001
1	Transforming Growth Factors (Transforming Growth Factor)IBA 07/2001
1	Progesterone Receptors (Progesterone Receptor)IBA 06/2001
1	Indicators and Reagents (Reagents)IBA 06/2001
1	Fluorouracil (Carac)FDA LinkGeneric 01/2001
1	idoxifeneIBA 12/2000
1	Antineoplastic Agents (Antineoplastics)IBA 12/2000
1	Toremifene (Fareston)FDA Link 12/2000
1	PlacebosIBA 07/2000
1	Angiogenesis InhibitorsIBA 07/2000
1	O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA 07/2000
1	LuciferasesIBA 01/2000
1	Epidermal Growth Factor (EGF)IBA 01/2000
1	EnzymesIBA 01/2000
1	AntibodiesIBA 01/2000
1	LipidsIBA 01/2000
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2000

Therapy/Procedure

7	Therapeutics 08/2001 - 01/2000
2	Chemoprevention 12/2001 - 01/2001
1	Drug Therapy (Chemotherapy) 01/2001
1	Mastectomy (Mammectomy) 01/2001